Study on infections in children with cancer has begun in Uganda

Infections are a leading cause of death during cancer treatment for children in sub-Saharan Africa. In October, the first child was enrolled in the MICRO-SCOPE study in Uganda.
At the paediatric oncology unit at Mbarara Regional Referral Hospital in south-western Uganda, 100 to 150 new paediatric patients are admitted each year. Survival for childhood cancer in the region is roughly where it was in Sweden in the 1960s.
– We want to find out which bacteria cause infections in the children during cancer treatment, and how often they are resistant to the antibiotics available, says Erik Larsson, paediatrician and project lead, who, together with Dr Giulia Gaudenzi, Department of Global Public Health, has launched the study on site.
The path to launch
The protocol was written in 2024 together with doctors at the hospital in Mbarara and the research institute Epicentre. The ethics committee in Uganda approved the study in June 2026, and recruitment opened on 12 October. Three weeks later, the study has begun and seven children have been enrolled.
Over two years, the researchers will follow 100 children and one adult in each child’s household, and take samples during 200 fever episodes. Bacterial cultures will be analysed at Epicentre’s laboratory, and some samples will be frozen for later sequencing of the gut microbiome at KI.
– Mortality from infections is high compared with Sweden. This is partly due to poorer conditions for diagnosing bacterial bloodstream infections, antibiotic resistance and access to the right antibiotics, says Anna Nilsson, professor of paediatric oncology at the Department of Women’s and Children’s Health.
The researchers hope that blood culture, which is the standard method in Sweden, can be introduced in Mbarara and thereby help paediatric oncologists on site in Mbarara with improved diagnostics.
– We hope the laboratory staff will become comfortable and experienced with this type of analysis. We also hope to see lower mortality from infections in children with cancer, says Anna Nilsson.
– What keeps the study going when I am not there is the team in Mbarara, says Erik Larsson, who is now travelling to Uganda again and will stay for a couple of weeks.
The study has received grants from Foundation for International Oncology Collaboration (SIOS), KI:s Afrika/LMIC-grant, the Einhorn Family Foundation, the Märta and Gunnar V Philipson Foundation, the Mary Béve Foundation for Childhood Cancer Research and the Bojana Nathorst-Böö Foundation for Paediatric Medical Training